Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Apr 26;5(3):e602.
doi: 10.1002/hsr2.602. eCollection 2022 May.

Treatment satisfaction and response in patients with severe alopecia areata under treatment with diphenylcyclopropenone

Robabeh Abedini  1 , Alireza Abdshah  1 , Narges Ghandi  1 , Atefe Janatalipour  1 , Sara Torabi  1 , Maryam Nasimi  1
Affiliations

Treatment satisfaction and response in patients with severe alopecia areata under treatment with diphenylcyclopropenone

Robabeh Abedini et al. Health Sci Rep. .

Erratum in

  • Corrigendum.
    Abedini R, Abdshah A, Ghandi N, Janatalipour A, Torabi S, Nasimi M. Abedini R, et al. Health Sci Rep. 2022 Sep 26;5(5):e848. doi: 10.1002/hsr2.848. eCollection 2022 Sep. Health Sci Rep. 2022. PMID: 36189404 Free PMC article.

Abstract

Background and aims: Alopecia areata (AA) is an autoimmune disease of hair follicles. Treatments currently include topical and intralesional corticosteroids and contact immunotherapy; however, the overall prognosis is usually unfavorable. In severe AA, topical immunotherapy with diphenylcyclopropenone (DPCP) is preferred. Since its effectiveness is heterogeneous and there are several side effects, we decided to measure the patients' satisfaction using the "Version II of the Treatment Satisfaction Questionnaire for Medication," which investigates satisfaction with effectiveness, side effects, convenience, and global satisfaction.

Methods: We examined 100 patients under treatment with DPCP for treatment response, asked them to respond to the questionnaire, and calculated their overall scores out of 400. We then investigated the association between the patients' characteristics with their treatment response and satisfaction.

Results: The overall satisfaction of patients was 257/400. We observed a significant association between patients' satisfaction scores on effectiveness and global satisfaction with their response to treatment (p < 0.001). The patients' satisfaction with the treatment's convenience had a significantly positive association with the age of receiving the diagnosis (p = 0.028). The overall treatment satisfaction was significantly associated with treatment response (276 vs. 213, p = 0.000).

Conclusion: Although there are currently no gold standard treatments for severe AA, DPCP demonstrated a 71% response to treatment, and patients with response were significantly more satisfied with their treatment.

Keywords: DPCP; TSQM; alopecia areata; treatment response; treatment satisfaction.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Petukhova L, Duvic M, Hordinsky M, et al. Genome‐wide association study in alopecia areata implicates both innate and adaptive immunity. Nature. 2010;466(7302):113‐117. - PMC - PubMed
    1. Nowicka D, Maj J, Jankowska‐Konsur A, Hryncewicz‐Gwóźdź A. Efficacy of diphenylcyclopropenone in alopecia areata: a comparison of two treatment regimens. Postepy Dermatol Alergol. 2018;35(6):577‐581. - PMC - PubMed
    1. Simakou T, Butcher JP, Reid S, Henriquez FL. Alopecia areata: a multifactorial autoimmune condition. J Autoimmun. 2019;98:74‐85. - PubMed
    1. Gilhar A, Kalish RS. Alopecia areata: a tissue specific autoimmune disease of the hair follicle. Autoimmun Rev. 2006;5(1):64‐69. - PubMed
    1. Amin SS, Sachdeva S. Alopecia areata: an update. J. Pak. Assoc. Dermatol. 2013;23:209‐220. http://www.jpad.com.pk/index.php/jpad/article/view/346

LinkOut - more resources